MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas

Sasaki,Hidefumi; Shitara,Masayuki; Yokota,Keisuke; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/mmr.2012.979

MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas

Authors:
- Hidefumi Sasaki
- Masayuki Shitara
- Keisuke Yokota
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: July 5, 2012 https://doi.org/10.3892/mmr.2012.979
Pages: 705-708

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The expression of multidrug-resistant protein-3 (MRP3), a membrane-bound transporter, has been linked to drug resistance in non-small cell lung cancers (NSCLCs). Recently, we reported that NRF2 gene (NFE2L2) mutations are correlated with poor prognosis for lung squamous cell carcinomas. We hypothesized that tumor MRP3 expression may be correlated with the mutation status of upstream regulators, including NRF2, in NSCLC patients. MRP3 mRNA levels were analyzed by quantitative real-time polymerase chain reaction (qPCR) in 67 surgically-treated lung squamous cell cancer cases from the Nagoya City University Hospital and normalized by β-actin mRNA levels. Fourteen NRF2 mutation cases were included. The mean MRP3/β-actin mRNA levels did not differ according to age (≤65 vs. >65 years), Brinkman index (≤400 vs. >400) or the pathological stage of the lung squamous cell carcinoma. MRP3/β-actin mRNA levels were significantly higher in men (1.200±1.524) than in women (0.179±0.083; p=0.0036). In addition, the MRP3/β-actin mRNA levels were significantly higher in NRF2 mutants (2.598±2.373) than in wild-type NRF2 mutants (0.734±0.820; p=0.0002). These data support the hypothesis that the expression of MRP3 is induced by NRF2 activation in lung squamous cell cancers.

View Figures

View References

1	Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. Cancer: Principles and Practice of Oncology. DeVita VT, Hellman S and Rosenberg SA: 4th edition. Lippincott, Williams and Wilkins; Philadelphia: pp. 673–682. 1993
2	Sakata R, Fujii Y and Kuwano H: Thoracic and cardiovascular surgery in Japan during 2009. Annual report by the Japanese Association for Thoracic Surgery Gen Thorac Cardiovasc Surg. 59:636–667. 2011.
3	Postus PE: Chemotherapy for non-small cell lung cancer: the experience of the lung cancer cooperative group of the European Organization for Research and Treatment of Cancer. Chest. 113(Suppl 1): S28–S31. 1998. View Article : Google Scholar : PubMed/NCBI
4	Kensler TW and Wakabayashi N: Nrf2: friend or foe for chemoprevention? Carcinogenesis. 31:90–99. 2010. View Article : Google Scholar : PubMed/NCBI
5	Moi P, Chank K, Asunis I, et al: Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc Natl Acad Sci USA. 91:9926–9930. 1994. View Article : Google Scholar
6	Solis LM, Behrens C, Dong W, et al: Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
7	Sasaki H, Hikosaka Y, Okuda K, et al: NFE2L2 gene mutation in male Japanese squamous cell carcinoma of the lung. J Thorac Oncol. 5:786–789. 2010. View Article : Google Scholar : PubMed/NCBI
8	Shibata T, Ohta T, Tong KI, et al: Cancer related mutations in Nrf2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA. 105:13568–13573. 2008. View Article : Google Scholar : PubMed/NCBI
9	Hu Y, Ju Y, Lin D, et al: Mutation of the Nrf2 gene in non-small cell lung cancer. Mol Biol Rep. 39:4743–4747. 2012. View Article : Google Scholar : PubMed/NCBI
10	Young LC, Campling BG, Voskoglou-Nomikos T, et al: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res. 5:673–680. 1999.PubMed/NCBI
11	Kool M, van der Linden M, de Haas M, et al: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA. 96:6914–6919. 1999. View Article : Google Scholar : PubMed/NCBI
12	Lockhart AC, Tirona RG and Kim RB: Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2:685–698. 2003.PubMed/NCBI
13	Mahaffey CM, Zhang H, Rinna A, et al: Multidrug resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small cell lung carcinoma. Free Radic Biol Med. 46:1650–1657. 2009. View Article : Google Scholar : PubMed/NCBI
10	Merikallio H, Pääkkö P, Kinnula VL, et al: Nuclear factor erythroid-derived 2-like 2 (Nrf2) and DJ1 are prognostic factors in lung cancer. Hum Pathol. 43:577–584. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yang H, Wang W, Zhang Y, et al: The role of NF-E2-related factor 2 in predicting chemoresistance and prognosis in advanced non-small cell lung carcinomas. Clin Lung Cancer. 12:166–171. 2011. View Article : Google Scholar : PubMed/NCBI
12	Mahaffey CM, Mahaffey NC, Holland W, et al: Aberrant regulation of the MRP3 gene in non-small cell lung carcinoma. J Thorac Oncol. 7:34–39. 2012. View Article : Google Scholar : PubMed/NCBI
13	Mahaffey CM, Zhang H, Rinna A, et al: Multidrug resistant protein-three gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small cell lung carcinoma. Free Radiac Biol Med. 46:1650–1657. 2009. View Article : Google Scholar : PubMed/NCBI
14	Itoh K, Chiba T, Takahashi S, et al: An Nef2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
15	Rushmore TH and Kong AN: Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab. 3:481–490. 2002. View Article : Google Scholar : PubMed/NCBI
16	Ngyyen T, Yang CS and Pickett CB: The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med. 37:433–441. 2004. View Article : Google Scholar : PubMed/NCBI
17	Singh A, Boldin-Adamsky S, Thimmulappa RK, et al: RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
18	Arisawa T, Tahara T, Shibata T, et al: Nrf2 gene promoter polymorphism and gastric carcinogenesis. Hepatogastroenterology. 55:750–754. 2008.PubMed/NCBI
19	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar
20	Zhou J, Schmid T, Schnitzer S and Brüne B: Tumor hypoxia and cancer progression. Cancer Lett. 237:10–21. 2006. View Article : Google Scholar
21	Homma S, Ishii Y, Morishima Y, et al: Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res. 15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
22	Cho JM, Manandhar S, Lee HR, et al: Role of Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 260:96–108. 2008. View Article : Google Scholar : PubMed/NCBI